1,3-二甲基-5-(丙-2-炔基氨基)嘧啶-2,4-二酮 | 105556-09-0

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪类
• 中文名称: 1,3-二甲基-5-(丙-2-炔基氨基)嘧啶-2,4-二酮
• 英文名称: 1,3-dimethyl-5-(prop-2-ynylamino)pyridine-2,4(1H,3H)-dione
• 英文别名: 1,3-dimethyl-5-propargylaminouracil；1,3-dimethyl-5-(prop-2-yn-1-ylamino)pyrimidine-2,4(1H,3H)-dione；1,3-Dimethyl-5-[(prop-2-yn-1-yl)amino]pyrimidine-2,4(1H,3H)-dione；1,3-dimethyl-5-(prop-2-ynylamino)pyrimidine-2,4-dione
• CAS: 105556-09-0
• 化学式: C₉H₁₁N₃O₂
• 分子量: 193.205
• InChiKey: IRXHCHDQRVLDGB-UHFFFAOYSA-N

物化性质

• 熔点：
  140-142 °C(Solv: ethyl acetate (141-78-6))
• 沸点：
  299.0±50.0 °C(Predicted)
• 密度：
  1.27±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  -0.3
• 重原子数：
  14
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.33
• 拓扑面积：
  52.6
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  1,3-二甲基-5-(丙-2-炔基氨基)嘧啶-2,4-二酮 在 silver hexafluoroantimonate 作用下， 以 二甲基亚砜 为溶剂， 反应 1.0h， 以89%的产率得到1,3-dimethylpyrido<2,3-d>pyrimidine-2,4-dione
  参考文献：
  名称：

  Regioselective Synthesis of Annulated Quinoline and Pyridine Derivatives by Silver-Catalyzed 6-endo-dig Cycloisomerization

  摘要：

  3H-吡喃并[3,2-f]喹啉-3-酮、4-甲基-4,7-二氢吩噻啉-3(4H)-酮和1,3-二甲基吡啶并[3,2-d]嘧啶-2,4(1H,3H)-二酮衍生物已经通过迄今未报道的银催化的6-endo-dig模式的环异构化反应从各种N-炔丙基化的杂环化合物中合成。这种银催化的反应为合成潜在的生物活性化合物提供了极佳的产率。

  DOI：

  10.1055/s-0030-1259097
• 作为产物：
  描述：

  5-氨基-1,3-二甲基嘧啶-2,4(1H,3H)-二酮 、 3-溴丙炔 以 甲醇 、 二氯甲烷 为溶剂， 以41%的产率得到1,3-二甲基-5-(丙-2-炔基氨基)嘧啶-2,4-二酮
  参考文献：
  名称：

  Simple syntheses of 1,3-dialkylpyrrolo- and furopyrimidines.

  摘要：

  通过分子内环化反应，从5-或6-取代嘧啶出发，简便高效地合成了7-脱氮咖啡因、9-脱氮茶碱、呋喃[2, 3-d]嘧啶和呋喃[3, 2-d]嘧啶。

  DOI：

  10.1248/cpb.33.4740

文献信息

• [EN] FUSED PYRIMIDINE-DIONE DERIVATIVES AS TRPA1 MODULATORS<br/>[FR] DÉRIVÉS DE PYRIMIDINEDIONES FUSIONNÉS UTILISÉS COMME MODULATEURS DES RÉCEPTEURS TRPA1
  申请人：GLENMARK PHARMACEUTICALS SA

  公开号：WO2010109287A1

  公开（公告）日：2010-09-30

  The invention described herein relates to novel fused pyrimidinediones derivatives of formula (I) which are TRPA (Transient Receptor Potential subfamily A) modulators. In particular, compounds described herein are useful for treating or preventing diseases, conditions and/or disorders modulated by TRPAl (Transient Receptor Potential subfamily A, member 1). This invention also provides processes for preparing compounds described herein, intermediates used in their synthesis, pharmaceutical compositions thereof, and methods for treating or preventing diseases, conditions and/or disorders modulated by TRPAl. Formula (I)

  本发明描述的是一类新颖的杂合吡啶二酮衍生物，其化学公式为（I），这些衍生物是TRPA（瞬时受体电位亚家族A）的调节剂。特别是，本文所述的化合物对于治疗或预防由TRPA1（瞬时受体电位亚家族A成员1）调控的疾病、状况和/或失调是有用的。本发明还提供了制备所述化合物、它们合成中使用的中间体、药物组合物以及治疗或预防由TRPA1调控的疾病、状况和/或失调的方法。公式（I）
• Simple syntheses of 1,3-dialkylpyrrolo- and furopyrimidines.
  作者：NORIO KAWAHARA、TAKAKO NAKAJIMA、TSUNEO ITOH、HARUO OGURA

  DOI：10.1248/cpb.33.4740

  日期：——

  Simple and efficient syntheses of 7-deazacaffeines, 9-deazatheophyllines, furo [2, 3-d] pyrimidines and furo [3, 2-d] pyrimidines from 5- or 6-substituted pyrimidines by means of intramolecular cyclization reactions are described.

  通过分子内环化反应，从5-或6-取代嘧啶出发，简便高效地合成了7-脱氮咖啡因、9-脱氮茶碱、呋喃[2, 3-d]嘧啶和呋喃[3, 2-d]嘧啶。
• FUSED PYRIMIDINE-DIONE DERIVATIVES AS TRPAI MODULATORS
  申请人：Chaudhari Sachin Sundarlal

  公开号：US20120041004A1

  公开（公告）日：2012-02-16

  The invention described herein relates to novel fused pyrimidinediones derivatives of formula (I) which are TRPA (Transient Receptor Potential subfamily A) modulators. In particular, compounds described herein are useful for treating or preventing diseases, conditions and/or disorders modulated by TRPA1 (Transient Receptor Potential subfamily A, member 1). This invention also provides processes for preparing compounds described herein, intermediates used in their synthesis, pharmaceutical compositions thereof, and methods for treating or preventing diseases, conditions and/or disorders modulated by TRPA1.

  本发明涉及化合物公式(I)的新型融合嘧啶二酮衍生物，其为TRPA（瞬时受体电位亚家族A）调节剂。特别地，本发明所描述的化合物可用于治疗或预防由TRPA1（瞬时受体电位亚家族A，成员1）调节的疾病、状况和/或障碍。本发明还提供了制备所述化合物的方法、用于其合成的中间体、其制药组合物以及用于治疗或预防由TRPA1调节的疾病、状况和/或障碍的方法。
• Fused pyrimidine-dione derivatives as TRPA1 modulators
  申请人：Chaudhari Sachin Sundarlal

  公开号：US08623880B2

  公开（公告）日：2014-01-07

  The invention described herein relates to novel fused pyrimidinediones derivatives of formula (I) which are TRPA (Transient Receptor Potential subfamily A) modulators. In particular, compounds described herein are useful for treating or preventing diseases, conditions and/or disorders modulated by TRPA1 (Transient Receptor Potential subfamily A, member 1). This invention also provides processes for preparing compounds described herein, intermediates used in their synthesis, pharmaceutical compositions thereof, and methods for treating or preventing diseases, conditions and/or disorders modulated by TRPA1.

  本发明涉及公式（I）的新型融合嘧啶二酮衍生物，其为TRPA（瞬时受体电位亚家族A）调节剂。特别地，本文所描述的化合物可用于治疗或预防由TRPA1（瞬时受体电位亚家族A，成员1）调节的疾病、病症和/或障碍。本发明还提供了制备所述化合物的工艺、用于其合成的中间体、其药物组成物以及治疗或预防由TRPA1调节的疾病、病症和/或障碍的方法。
• FUSED PYRIMIDINE-DIONE DERIVATIVES AS TRPA1 MODULATORS
  申请人：Glenmark Pharmaceuticals, S.A.

  公开号：US20140128603A1

  公开（公告）日：2014-05-08

  The invention described herein relates to novel fused pyrimidinediones derivatives of formula (I) which are TRPA (Transient Receptor Potential subfamily A) modulators. In particular, compounds described herein are useful for treating or preventing diseases, conditions and/or disorders modulated by TRPA1 (Transient Receptor Potential subfamily A, member 1). This invention also provides processes for preparing compounds described herein, intermediates used in their synthesis, pharmaceutical compositions thereof, and methods for treating or preventing diseases, conditions and/or disorders modulated by TRPA1.

  本发明涉及式（I）的新型融合嘧啶二酮衍生物，其为TRPA（瞬时受体电位亚家族A）调节剂。特别地，本发明所描述的化合物可用于治疗或预防由TRPA1（瞬时受体电位亚家族A，成员1）调节的疾病、状况和/或紊乱。本发明还提供了制备所述化合物的方法、用于其合成的中间体、其药物组成物以及用于治疗或预防由TRPA1调节的疾病、状况和/或紊乱的方法。